Outcomes and impact
We evaluated each opportunity to prioritize those with the highest market value and easiest route to approval.
In total, we identified 6 priority opportunities to reposition assets in high-value indications within the company’s key therapeutic areas. These opportunities were mainly in late-stage trials with an already established safety profile and two of the opportunities were for drugs already approved and on-market.
The analysis also revealed 5 opportunities for the company to reposition their assets in other non-core therapeutic areas, potentially as out-licensing opportunities with other biopharma partners.
Each opportunity included a detailed multi-parameter evaluation, supporting data package with patient stratification biomarkers, and high efficacy prediction scores to minimize the risk of expensive trial failures due to efficacy and enable effective new treatments to get to market quicker.